Slate Medicines to Merge With Fulcrum Therapeutics
August 19, 2026
August 19, 2026
PALO ALTO, California, Aug. 19 -- Cooley, a law firm, issued the following news release:
* * *
Slate Medicines to Merge With Fulcrum Therapeutics
Cooley advised Slate Medicines, a biotechnology company developing next-generation therapeutics for the treatment of migraine, on its definitive agreement to combine with Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, in an all-stock reverse merger transaction. Upon completion of the merger, the . . .
* * *
Slate Medicines to Merge With Fulcrum Therapeutics
Cooley advised Slate Medicines, a biotechnology company developing next-generation therapeutics for the treatment of migraine, on its definitive agreement to combine with Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, in an all-stock reverse merger transaction. Upon completion of the merger, the . . .